Publications
70
Citations
2,721
Est. group size
~2
Recurring co-author estimate
Active years
19
Publishing since 2007
Typically publishes in teams of ~13 · 10% small-team papers (≤3 authors) · across 13 venues
- Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)
Journal of Medicinal Chemistry · 2025
- Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Abstract LB127: An unconventional antiestrogen reveals the novel therapeutic target, DKK1, in aggressive ER+ breast cancer
Cancer Research · 2025
- Abstract P2-06-08: A Novel SERM Reinvigorates Natural Killer Cells by Uniquely Downregulating DKK1 in Breast Cancer Cells
Clinical Cancer Research · 2025
- Pleiotropic anti-cancer activities of novel non-covalent thioredoxin reductase inhibitors against triple negative breast cancer
Free Radical Biology and Medicine · 2024
- Abstract 6045: Development and characterization of ATC-324: An AUTOTAC-based androgen receptor degrader for prostate cancer treatment
Cancer Research · 2024
- Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer Cells
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- 8464 A Unique SERM Reveals an Estrogen Receptor-Dependent Secretion of DKK1 in Breast Cancer Cells
Journal of the Endocrine Society · 2024
- 8464 A Unique SERM Reveals An Estrogen Receptor-Dependent Secretion Of DKK1 In Breast Cancer Cells
Journal of the Endocrine Society · 2024
- SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis
Cancer Letters · 2023
- Editorial: Hormone resistance in cancer
Frontiers in Endocrinology · 2023
- OR05-05 A Novel Model Of Prostate Cancer Suggests Enzalutamide Functions Through The Immune System To Diminish Castration Resistant And Metastatic Growth
Journal of the Endocrine Society · 2023
- THU546 A Lasofoxifene/Elacestrant Hybrid Antiestrogen Shows Effective Anti-tumoral Activities In Y537S ESR1 Breast Cancer Xenografts
Journal of the Endocrine Society · 2023
- SOX2 mediates metabolic reprogramming of prostate cancer cells
Oncogene · 2022
- Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells
Oncogene · 2022
- Cancer Research×9
- Journal of the Endocrine Society×4
- Nature×3
- Neoplasia×3
- bioRxiv (Cold Spring Harbor Laboratory)×3
- William K. Storck
Medicine · University of Michigan
- Anbarasu Kumaraswamy
Medicine · University of Michigan
- Armand Bankhead
Medicine · University of Michigan
- Abhijit Parolia
Medicine · University of Michigan
- AM Chinnaiyan
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile